Research analysts at Cantor Fitzgerald issued their FY2025 earnings estimates for shares of Neurocrine Biosciences in a report released on Tuesday, January 21st. Cantor Fitzgerald analyst J. Schimmer ...

such as late-onset congenital adrenal hyperplasia and Cushing's syndrome. The more recent 2003 Rotterdam consensus workshop was in response to an increasing awareness that the clinical expression ...

Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced that Andrew Ratz, Ph.D., has joined the company as Senior Vice ...

HB Wealth Management LLC bought a new stake in shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX – Free Report) during the ...